Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I: Comparison between Healthy Subjects and Patients with Hypertension
Biomarkers are increasingly used to provide decision making data early in phase I by showing Proof of Mechanism or Proof of Concept (PoM/PoC). For antihypertensive agents, the administration of multiple doses (md) to hypertensive patients is assumed to be necessary for an early go/no-go decision. We...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2007-01-01
|
| Series: | Biomarker Insights |
| Online Access: | http://la-press.com/article.php?article_id=197 |